General information

The pharmacist has dispensed Adempas® 0.5 or 1mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this medicine has therefore instructed TBR Nederland to reimburse to the patient the Personal Contribution charged.

Dose 0.5 and 1mg
Type Tablets
Active ingredient RIOCIGUAT

Reimbursement

Conditions

The Personal Contribution for Adempas® 0.5 and 1mg charged to the patient by the health insurer, is eligible for full reimbursement from 1 January 2019 to a maximium of € 250,- per patient per year. Therefore, the patient can submit a claim with TBR Nederland.

As off May 31st 2023, the reimbursement for Adempas®0.5 mg and 1.0 mg is now also indicated for the treatment of PAH in pediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists. 

Who can submit a claim

Patients or their carer can submit a claim for the Personal Contribution amount they paid for Adempas® 0.5 and 1mg, either online or by post. Pharmacists cannot submit claims on behalf of patients for this medicine.

From when till when can you submit a claim

For this Reimbursement Scheme no closing date has been determined yet.

Submit a claim online

Patients can claim online and will receive their reimbursement within 5 working days.

Read our tips on how to submit a claim online

Login & Submit a Claim          Open an Online Account

 


Submit a claim by post

Patients can claim by post and will receive their reimbursement within 15 working days.

Read our tips on how to submit your claim by post

Please mail the Claim Form and attachments to:

TBR Nederland
Postbus 8011
1180 LA Amstelveen 

Check your medicine expenses

Quickly check the maximum contribution you have to pay for your medicine

Check Medicine Expenses

PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS

Select your medicine

You are currently offline. Some pages or content may fail to load.